Metformina Pharmconsul

Metformin Hydrochloride, the active ingredient in Metformina Pharmconsul, is a biguanide presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control elevated blood glucose levels.

GNH USA supplies Metformina Pharmconsul as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions. Its distribution network ensures timely delivery and regulatory compliance for each shipment.

Metformina Pharmconsul (metformin) is used to improve glycaemic control in disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to achieve target HbA1c. - Prediabetes (impaired fasting glucose): delays progression to overt diabetes by improving insulin sensitivity. - Polycystic ovary syndrome (off‑label): reduces insulin resistance and may help restore ovulatory cycles.

Metformina Pharmconsul may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption over long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Severe hypoglycaemia: when combined with insulin or sulfonylureas. - Hepatic dysfunction: worsening liver disease may increase risk. - Skin reactions: rash or urticaria. - Renal impairment: accumulation leading to toxicity. - Anaphylactic reaction: extremely rare hypersensitivity.

Before initiating Metformina Pharmconsul, clinicians should evaluate patient‑specific risk factors and monitor therapy. - Renal function: assess eGFR and avoid use if severely reduced. - Lactic acidosis risk: contraindicated in hepatic impairment or conditions predisposing to hypoxia. - Alcohol consumption: limit intake to reduce lactic acidosis potential. - Monitoring: periodic measurement of blood glucose, HbA1c, and vitamin B12 levels. - Pregnancy: use only if potential benefit justifies risk to the fetus. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metformina Pharmconsul can interact with several medicines, requiring caution.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure. - Cimetidine: can increase metformin plasma concentrations. - Alcohol: heightens risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes.